Equities Analysts Set Expectations for DNLI FY2025 Earnings

Denali Therapeutics Inc. (NASDAQ:DNLI) – Research analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Denali Therapeutics in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer anticipates that the company will earn ($2.86) per share for the year. Cantor Fitzgerald currently has a “Neutral” rating on the stock. The consensus estimate for Denali Therapeutics’ current full-year earnings is ($2.73) per share.

DNLI has been the topic of a number of other reports. Baird R W upgraded shares of Denali Therapeutics to a “strong-buy” rating in a research note on Tuesday, January 7th. Stifel Nicolaus upgraded shares of Denali Therapeutics from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Monday, December 16th. JPMorgan Chase & Co. dropped their price target on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating for the company in a research note on Tuesday, January 7th. Jefferies Financial Group increased their price objective on Denali Therapeutics from $40.00 to $45.00 and gave the company a “buy” rating in a research note on Friday, November 1st. Finally, Robert W. Baird assumed coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They set an “outperform” rating and a $31.00 target price for the company. Two research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $38.91.

Denali Therapeutics Trading Up 1.2 %

DNLI stock opened at $23.31 on Wednesday. The business’s fifty day moving average price is $22.68 and its 200 day moving average price is $24.80. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The company has a market capitalization of $3.35 billion, a PE ratio of -8.45 and a beta of 1.39.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.03). During the same period in the prior year, the business posted ($0.72) earnings per share.

Insider Buying and Selling

In related news, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction on Monday, January 6th. The shares were sold at an average price of $20.22, for a total transaction of $591,758.52. Following the sale, the chief executive officer now directly owns 260,721 shares in the company, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Steve E. Krognes sold 3,339 shares of the company’s stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the transaction, the director now owns 25,757 shares of the company’s stock, valued at $536,003.17. This represents a 11.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 64,518 shares of company stock worth $1,469,382 over the last 90 days. 7.90% of the stock is owned by insiders.

Institutional Trading of Denali Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in DNLI. FMR LLC grew its stake in Denali Therapeutics by 3,234.3% during the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after buying an additional 7,596,508 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in shares of Denali Therapeutics by 63.2% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,749,486 shares of the company’s stock worth $109,223,000 after acquiring an additional 1,451,770 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in shares of Denali Therapeutics in the 2nd quarter valued at $24,454,000. Wellington Management Group LLP increased its holdings in shares of Denali Therapeutics by 9.2% in the 3rd quarter. Wellington Management Group LLP now owns 10,727,450 shares of the company’s stock valued at $312,491,000 after acquiring an additional 903,683 shares during the period. Finally, Marshall Wace LLP boosted its stake in Denali Therapeutics by 12.7% during the 2nd quarter. Marshall Wace LLP now owns 2,418,833 shares of the company’s stock worth $56,165,000 after purchasing an additional 272,454 shares during the period. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.